The company's US subsidiary, would commence marketing the product shortly
Lupin Pharma has announced that the US Food and Drugs Administration (US FDA) has approved its Vancocin capsules. Lupin's vancomycin capsules are the AB rated generic equivalent of ANI Pharmaceuticals Vancocin capsules and are indicated for the treatment of C. difficile-associated diarrhoea and also for the treatment of enterocolitis caused by staphylococcus aureus (including methicillin-resistant strains). The company's US subsidiary, would commence marketing the product shortly.
The company has received final approval for its Vancomycin Hydrochloride Capsules in strengths of 125 mg and 250 mg.
According to IMS MAT September, 2014, Vancocin capsules had annual sales of $164.2 million in the US.